How has Leonard Schleifer's remuneration changed compared to Regeneron Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2025	n/a	n/a	US$5b
Jun 30 2025	n/a	n/a	US$4b
Mar 31 2025	n/a	n/a	US$4b
Dec 31 2024	US$7m	US$2m	US$4b
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$4b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$8m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b

Compensation vs Market: Leonard's total compensation ($USD6.82M) is below average for companies of similar size in the US market ($USD13.27M).

Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.

CEO

Leonard Schleifer (72 yo)

38yrs

Tenure

US$6,823,034

Compensation

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Leonard Schleifer	Co-Founder	38yrs	US$6.82m	2.35% $ 1.8b
George Yancopoulos	Co-Founder	25yrs	US$6.80m	1.14% $ 892.0m
Christopher Fenimore	Executive VP of Finance & CFO	1.9yrs	US$6.27m	0.021% $ 16.6m
Andrew Murphy	Executive VP of Research & Co-Chief Scientific Officer	7yrs	US$8.36m	0.051% $ 39.9m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	17.8yrs	US$8.66m	0.034% $ 26.9m
Rajesh Ahuja	Senior Vice President of Quality Assurance & Operations	1yr	no data	no data
Bob McCowan	Senior VP of IT & Chief Information Officer	5yrs	no data	no data
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	no data	no data
Joseph LaRosa	Executive VP	14.3yrs	US$7.13m	0.041% $ 32.3m
Melissa Lozner	Senior VP & Chief Compliance Officer	3yrs	no data	no data
Sally Paull	Executive Vice President of Human Resources	9.8yrs	no data	no data
Maya Bermingham	Senior Vice President of Public Policy & Government Affairs	5yrs	no data	no data

7.0yrs

Average Tenure

65.5yo

Average Age

Experienced Management: REGN's management team is seasoned and experienced (7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Leonard Schleifer	Co-Founder	38yrs	US$6.82m	2.35% $ 1.8b
George Yancopoulos	Co-Founder	25yrs	US$6.80m	1.14% $ 892.0m
Christine Poon	Lead Independent Director	15.2yrs	US$769.77k	0.0034% $ 2.7m
Arthur Ryan	Independent Director	23yrs	US$719.77k	0.016% $ 12.4m
Michael Brown	Independent Director	34.6yrs	US$724.77k	0.011% $ 8.5m
Joseph Goldstein	Independent Director	34.6yrs	US$709.77k	0.0049% $ 3.8m
George Sing	Independent Director	38yrs	US$724.77k	0.032% $ 25.2m
N. Coles	Independent Director	9yrs	US$699.77k	0.000010% $ 7.8k
Craig Thompson	Independent Director	3.3yrs	US$699.77k	0% $ 0
Huda Zoghbi	Independent Director	9.3yrs	US$714.77k	0% $ 0
Bonnie Bassler	Independent Director	9.3yrs	US$709.77k	0.0015% $ 1.2m
Kathryn Guarini	Independent Director	2.3yrs	US$288.99k	0% $ 0

19.1yrs

Average Tenure

72yo

Average Age

Experienced Board: REGN's board of directors are seasoned and experienced ( 19.1 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/06 14:02
End of Day Share Price	2026/01/06 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Regeneron Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Independent Director exercised options to buy US$2.3m worth of stock.

Co-Founder exercised options and sold US$23m worth of stock

Executive VP exercised options and sold US$2.3m worth of stock

Insider exercised options and sold US$2.2m worth of stock

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2025

Recent updates

Regeneron Pharmaceuticals, Inc. to Report Q4, 2025 Results on Jan 30, 2026

Independent Director exercised options to buy US$2.3m worth of stock.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Regeneron: The Turnaround Is Gaining Steam

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Co-Founder exercised options and sold US$23m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Lynozyfic Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Executive VP exercised options and sold US$2.3m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Announces FDA Approval Of EYLEA HD Injection 8 Mg For Treatment Of Macular Edema Following Retinal Vein Occlusion And Monthly Dosing Across Approved Indications

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc

Upcoming dividend of US$0.88 per share

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Regeneron Pharmaceuticals, Inc. Announces Detailed Positive Phase 2 Trial Results Evaluating Two Novel Investigational Factor Xi Antibodies - Regn7508cat and Regn9933a2

Insider exercised options and sold US$2.2m worth of stock

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 05, 2025

Consensus EPS estimates increase by 15%

Regeneron Pharmaceuticals, Inc. Announces European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion for Libtayo (Cemiplimab)

Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the PD-1 Inhibitor Libtayo(Cemiplimab-Rwlc) as an Adjuvant Treatment for Adult Patients

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals Announces FDA Review Extension for EYLEA HD® Prefilled Syringe and Expanded Indications

Upcoming dividend of US$0.88 per share

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Declares A Cash Dividend on the Common Stock and Class A Stock, Payable on September 3, 2025

Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index

Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Price target decreased by 7.4% to US$738

Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass

Investor sentiment deteriorates as stock falls 17%

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Regeneron Pharmaceuticals, Inc. Announces Initial Results from Two Cohorts of the Phase 1B Linker-Mm2 Trial Evaluating Linvoseltamab in Combination with Two Different Proteasome Inhibitors

Undisclosed acquirer proposed to acquire 23andMe Holding Co. (OTCPK:MEHC.Q) for approximately $260 million.

Upcoming dividend of US$0.88 per share

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Regeneron Pharmaceuticals, Inc. Announces 24 Abstracts on Dupixent (Dupilumab) Clinical Data and Real-World Analyses in Respiratory Diseases

Price target decreased by 8.6% to US$808

Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Regeneron Pharmaceuticals, Inc. Announces Approval in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Provides Update on EYLEA HD®? (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts EYLEA HD (aflibercept) Injection 8 mg

Biocon Biologics Ltd Announces Settlement and License Agreement with Regeneron

Regeneron: Still A Biotech Juggernaut

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2025

Dupixent And EYLEA Will Open New Therapeutic Frontiers

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Regeneron Pharmaceuticals, Inc. to Report Q1, 2025 Results on Apr 29, 2025

Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Linvoseltamab Recommends for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts odronextamab BLA for the Treatment of Relapsed/Refractory Follicular Lymphoma

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

U.S. Food and Drug Administration Accepts Linvoseltamab BLA for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces First Presentation of Positive Results from the Phase 3 QUASAR Trial

Full year 2024 earnings: EPS misses analyst expectations

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Regeneron Pharmaceuticals, Inc. Approves the Initiation of A Quarterly Cash Dividend Program and Declares A Cash Dividend, Payable on March 20, 2025